Despite increasing graft survival rates associated with advances in immunosuppression, the relative risk of graft loss for transplants with HLA mismatches has remained at about 25% higher than those with 0 ABDR-mismatches. The percentage of 0 DR-mismatched transplants peaked at 25% in 1994 and has decreased yearly to 15% in 2003. The percentage of transplants with a flow crossmatch increased from 5% in 1988 to 38% in 2003. Prior to 1995, a flow crossmatch was associated with a decreased risk of graft loss. Antigen distributions of HLA-A, -B, -DR and CREGs are summarized and reveal many differences between Whites and Blacks. HLA matching models with 9, 18 and 36 CREGs are presented. The more complex models yielded fewer cases but outcomes approached that achieved for 0 ABDR-mismatched transplanted.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A review on disease modifying pharmacologic therapies for sickle cell disease.
Ann Hematol
January 2025
Department of Internal Medicine, Section of Hematology/Oncology, University of Missouri-Kansas City, Kansas City, MO, 64108, USA.
Sickle cell disease (SCD) is an inherited hematologic disease caused by sickle hemoglobin as the predominant RBC hemoglobin or by sickle hemoglobin in combination with other abnormal β-hemoglobin variants like HbC, HbD and others. Sickling of erythrocytes under deoxygenated conditions is the basis of inflammatory and thrombotic cascades which result in multiple serious complications, leading to early morbidity and mortality. While HLA-matched allogeneic bone marrow transplantation is potentially curative, it has considerable limitations due to potential severe toxicities.
View Article and Find Full Text PDFNovel Approach to Vascular Thymic Tissue Transplantation in Humans: A Case Report.
Transplant Proc
January 2025
Departamento de Imágenes Diagnósticas, Fundación Valle del Lili, Cali, Colombia.
Background: Vascular thymus transplantation has been explored in animal models but remains untested in humans. Current approaches to congenital athymia involve avascular transplantation of allogeneic thymic tissue, which may delay immune recovery. Building on animal studies, we propose revascularization of thymic tissue in a human model.
View Article and Find Full Text PDFiPSC stem cell banks: is it really necessary if we already have cord blood banks?
Regen Med
January 2025
Biorepository, University of Arizona, Tucson, AZ, USA.
ATAD2 is a potential immunotherapy target for patients with small cell lung cancer harboring HLA-A∗0201.
EBioMedicine
January 2025
State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing, 100021, China. Electronic address:
Background: Small cell lung cancer (SCLC) represents a highly aggressive neuroendocrine tumour with a dismal prognosis. Currently, the identification of a specific tumour antigen that can facilitate immune-based therapies for SCLC remains elusive.
Methods: We employed liquid chromatography-tandem mass spectrometry (LC-MS/MS) to analyse cancer/testis antigens (CTAs) in SCLC cell lines and human tumour specimens.
A standards-based application for improving platelet transfusion workflow.
J Pathol Inform
January 2025
Harvard Medical School, Boston, MA, United States of America.
Objective: Thrombocytopenia is a common complication of hematopoietic stem-cell transplantation (HSCT), though many patients will become immune refractory to platelet transfusions over time. We built and evaluated an electronic health record (EHR)-integrated, standards-based application that enables blood-bank clinicians to match platelet inventory with patients using data previously not available at the point-of-care, like human leukocyte antigen (HLA) data for donors and recipients.
Materials And Methods: The web-based application launches as an EHR-embedded application or as a standalone application.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!